in vitro Diagnostics.
Ensure and validate at every step of the way.
Immunoassays provide a fast, simple, and cost-effective method of detection with high sensitivity and specificity. They exploit antibodies’ properties to identify pathogens, cancer, and other disease biomarkers, drugs, and other analytes. Without a secure stream of validated monoclonal antibodies (mAbs), IVD developers risk nonspecific binding, batch variability, or loss of supply. At the discovery and development stage, the latter can result in wasted time and resources, or worse, project abandonment, while downstream, during manufacturing, it can lead to substantial costs.
By sequencing the protein of the antibody reagent in parallel to assessing the antibody’s affinity and specificity prior to use, scientists, kit, and reagent manufacturers can eliminate unforeseen surprises. Furthermore, obtaining the protein sequence enables recombinant expression, yielding more consistent batches with predictable biological activity. Next-generation protein sequencing (NGPS) can also help avoid issues with mAbs stemming from cell line drift, gene loss, and gene mutations. Rapid Novor’s NGPS has facilitated the development of reliable kits and immunoreagents securing scientists’ research reproducibility and their trust.
Services for in vitro diagnostic developers.
We support IVD companies and reagent manufacturers in all stages of antibody selection, development, characterization, validation and production. Contact us to discover how we can help with your IVD application.
de novo mAb Sequencing
Safeguard the sequence of high-demand immunoreagents for posterity, and/or IP, or to meet regulatory guidelines.
Explore REmAb
Fast ADA assays
Custom anti-drug antibody (ADA) control reagents assess clinical safety and efficacy in biologics and biosimilars. ADAs derived from the circulating polyclonal antibodies (pAb) can be easily derived by polyclonal antibody sequencing.
Explore REpAb + Expression
Quality Control and Troubleshooting
Routinely certify immunoreagents by confirming the expected sequence for the highest quality and minimal troubleshooting.
Explore MATCHmAb
Application Publications.
Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Generation and Diversification of Recombinant Monoclonal Antibodies
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Camelid Antibodies and Nanobodies
Written by Yuning Wang, PhD Contents Discovery of camelid antibodies What are camelid antibodies? Structure of camelid antibodies [...]
Recombinant Antibodies: A New Generation Enabled by Protein Sequencing
Written by María Gerpe, PhD Contents What are recombinant antibodies? What is the difference between recombinant and traditional [...]
“The protein sequence allowed us to control the antibody, affinity maturation, and do large production. Being able to produce 20mg of Ab is big advantage.”
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics